Telitacicept and Tacrolimus Synergy in Managing Refractory Primary Membranous Nephropathy: Case Insights

Renwei Huang; Yuhe Yin; Zewen Zhao; Xiaoying Dong; Chao Chen; Haowen Lin; Yiming Tao; Siqi Peng; Sichun Wen; Bohou Li; Qiong Wu; Sijia Li; Ting Lin; Hao Dai; Feng Wen; Zhuo Li; Lixia Xu; Jianchao Ma; Shuangxin Liu; Zhonglin Feng

doi:10.12659/AJCR.946727

23 April 2025 : Case report China

Telitacicept and Tacrolimus Synergy in Managing Refractory Primary Membranous Nephropathy: Case Insights

Unusual or unexpected effect of treatment

Renwei Huang

^1EF, Yuhe Yin^1EF, Zewen Zhao^1EF, Xiaoying Dong^1BC, Chao Chen^2B, Haowen Lin^13BC, Yiming Tao^1BC, Siqi Peng^1BC, Sichun Wen^1BC, Bohou Li^1BC, Qiong Wu^1D, Sijia Li^1D, Ting Lin^1D, Hao Dai^1D, Feng Wen^1D, Zhuo Li^1D, Lixia Xu^1D, Jianchao Ma^1D*, Shuangxin Liu^1AG, Zhonglin Feng^1A

DOI: 10.12659/AJCR.946727

Am J Case Rep 2025; 26:e946727

Authors information Article notes Copyright and License information

Introduction Case Report Discussion Conclusions References:

Related articles Order reprints Share article Share by email

View HTML version

Figure 1. Results of renal biopsy pathology. (A) Immunofluorescence staining indicates weak positivity for PLA2R. (B) Masson staining, the red arrow shows subepithelial eosinophilic deposition. (C) PASM staining, the blue thin arrow indicates a peg-like structure. (D) Electron microscopy, the blue bold arrow indicates the deposition of electron-dense material. PLA2R – phospholipase A2 receptor.

Back to the Article

Telitacicept and Tacrolimus Synergy in Managing Refractory Primary Membranous Nephropathy: Case Insights

Your Privacy